Skip to main content
. 2024 Oct 3;20(11):7788–7804. doi: 10.1002/alz.14246

FIGURE 2.

FIGURE 2

AG03 utilizes the VQIK(Ac)YKP recognition sequence. Aggregation end‐point measurements using ThT fluorescence after 24 h from 20 µM TauΔ1‐250 and/or 20 µM peptide inhibitor in the presence of 30 mM Tris buffer, 1 mM DTT, 15 µM ThT, 5 µM heparin (pH 7.4). (A) Aggregation of TauΔ1‐250 with different peptide inhibitors in the presence of heparin (white, hatched) and attempted self‐assembly of inhibitors without the presence of Tau (black). Key: AG01 [RG‐VQIINK‐GR], AG02 [RG‐VQIVYK‐GR], AG02R4 [RRG‐VQIVYK‐GRR], AG02R5 [RG‐VQIVYK‐GRRRR], AGR502 [RRRRG‐VQIVYK‐GR], AG02PR5 [RG‐VQIVYKP‐GRRRR], AG02R9 [RG‐VQIVYK‐GRRRRRRRR], AG02TAT [RG‐VQIVYKGRYGRKKRRQRRR], AG02ΔI [RG‐VQK(Ac)VYK‐GR], AG02ΔV [RG‐VQIK(Ac)YK‐GR], AG03 [RG‐VQIK(Ac)YKP‐GRRRRRRRR]. (B) Aggregation of TauΔ1‐250 in the presence of heparin with either octa‐arginine, scrambled AG03 peptide, AG03, N‐methylated AG03, or retro‐inverso AG03. Experiments were conducted in triplicate and error bars were reported as standard deviation. Statistical analysis: p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.